Clinical features of mantle cell lymphoma in hungary

S. Modok, Z. Borbenyi, L. Krenács, K. Piukovics, V. Hodi, G. Szedlak, L. Ivanyi, G. Varga

Research output: Contribution to journalArticle

Abstract

Background: Novel diagnostic techniques such as immunophenotyping and molecular genetic analysis have enabled us to recognize new entities such as mantle cell lymphoma (MCL). Typically, MCLs originate from CD5+/CDI9+/CD23- cells and have characteristic genetic markers (bel-1 overexpression due to t( 11 ; 14)). Despite an increasing understanding of this lymphoma subtype the clinical outcome is still poor. Objectives: The presenting features of MCL and response to chemotherapy were investigated by the authors. Results: Altogether 69 patients were diagnosed with MCL in Szeged and in Szombathely, it is about 10% of all NHL's. The mean age was 63.22±11.10 years and only five patients had 2 or worse performance score at diagnosis. Slight male predominance was observed ( 11:9). Elastic variants were described in 26 patients (37.7%). Extranodal presentation was frequent (27 pts, 39.1%). Most patients were diagnosed at advanced Ann Arbor stages III and IV (39 pts, 56.6%). Thirtysix pts recieved doxorubicin-based first-line chemotherapy. Fortyfive pts responded (26 complete and 19 partial remissions). The mean overall survival was 41.71+5.94 months and time to treatment failure was 21.97±2.9 months for the whole group. We observed only 7 second partial remissions. The time to treatment failure was longer for pts treated with doxorubicin-based chemotherapy (mean TTF: 27.1313.63 vs. 10.93+3.18 months), but only a slight benefit regarding overall survival were found (mean OS: 43.05±6.44 vs. 32.44±7.56 months) compared to the effect of other treatment protocols. Conclusions: MCL has the same features in Hungary, as in other parts of the world. The clinical outcome with conventional chemotherapy is poor, thus younger patients are candidates for high-dose chemotherapy and stem cell rescue in first remission.

Original languageEnglish
JournalBlood
Volume96
Issue number11 PART II
Publication statusPublished - 2000

Fingerprint

Mantle-Cell Lymphoma
Chemotherapy
Hungary
Drug Therapy
Treatment Failure
Doxorubicin
Immunophenotyping
Survival
Clinical Protocols
Stem cells
Genetic Markers
Molecular Biology
Lymphoma
Stem Cells

ASJC Scopus subject areas

  • Hematology

Cite this

Modok, S., Borbenyi, Z., Krenács, L., Piukovics, K., Hodi, V., Szedlak, G., ... Varga, G. (2000). Clinical features of mantle cell lymphoma in hungary. Blood, 96(11 PART II).

Clinical features of mantle cell lymphoma in hungary. / Modok, S.; Borbenyi, Z.; Krenács, L.; Piukovics, K.; Hodi, V.; Szedlak, G.; Ivanyi, L.; Varga, G.

In: Blood, Vol. 96, No. 11 PART II, 2000.

Research output: Contribution to journalArticle

Modok, S, Borbenyi, Z, Krenács, L, Piukovics, K, Hodi, V, Szedlak, G, Ivanyi, L & Varga, G 2000, 'Clinical features of mantle cell lymphoma in hungary', Blood, vol. 96, no. 11 PART II.
Modok S, Borbenyi Z, Krenács L, Piukovics K, Hodi V, Szedlak G et al. Clinical features of mantle cell lymphoma in hungary. Blood. 2000;96(11 PART II).
Modok, S. ; Borbenyi, Z. ; Krenács, L. ; Piukovics, K. ; Hodi, V. ; Szedlak, G. ; Ivanyi, L. ; Varga, G. / Clinical features of mantle cell lymphoma in hungary. In: Blood. 2000 ; Vol. 96, No. 11 PART II.
@article{fdb153b85517448581e5b6aeaae51a5a,
title = "Clinical features of mantle cell lymphoma in hungary",
abstract = "Background: Novel diagnostic techniques such as immunophenotyping and molecular genetic analysis have enabled us to recognize new entities such as mantle cell lymphoma (MCL). Typically, MCLs originate from CD5+/CDI9+/CD23- cells and have characteristic genetic markers (bel-1 overexpression due to t( 11 ; 14)). Despite an increasing understanding of this lymphoma subtype the clinical outcome is still poor. Objectives: The presenting features of MCL and response to chemotherapy were investigated by the authors. Results: Altogether 69 patients were diagnosed with MCL in Szeged and in Szombathely, it is about 10{\%} of all NHL's. The mean age was 63.22±11.10 years and only five patients had 2 or worse performance score at diagnosis. Slight male predominance was observed ( 11:9). Elastic variants were described in 26 patients (37.7{\%}). Extranodal presentation was frequent (27 pts, 39.1{\%}). Most patients were diagnosed at advanced Ann Arbor stages III and IV (39 pts, 56.6{\%}). Thirtysix pts recieved doxorubicin-based first-line chemotherapy. Fortyfive pts responded (26 complete and 19 partial remissions). The mean overall survival was 41.71+5.94 months and time to treatment failure was 21.97±2.9 months for the whole group. We observed only 7 second partial remissions. The time to treatment failure was longer for pts treated with doxorubicin-based chemotherapy (mean TTF: 27.1313.63 vs. 10.93+3.18 months), but only a slight benefit regarding overall survival were found (mean OS: 43.05±6.44 vs. 32.44±7.56 months) compared to the effect of other treatment protocols. Conclusions: MCL has the same features in Hungary, as in other parts of the world. The clinical outcome with conventional chemotherapy is poor, thus younger patients are candidates for high-dose chemotherapy and stem cell rescue in first remission.",
author = "S. Modok and Z. Borbenyi and L. Kren{\'a}cs and K. Piukovics and V. Hodi and G. Szedlak and L. Ivanyi and G. Varga",
year = "2000",
language = "English",
volume = "96",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11 PART II",

}

TY - JOUR

T1 - Clinical features of mantle cell lymphoma in hungary

AU - Modok, S.

AU - Borbenyi, Z.

AU - Krenács, L.

AU - Piukovics, K.

AU - Hodi, V.

AU - Szedlak, G.

AU - Ivanyi, L.

AU - Varga, G.

PY - 2000

Y1 - 2000

N2 - Background: Novel diagnostic techniques such as immunophenotyping and molecular genetic analysis have enabled us to recognize new entities such as mantle cell lymphoma (MCL). Typically, MCLs originate from CD5+/CDI9+/CD23- cells and have characteristic genetic markers (bel-1 overexpression due to t( 11 ; 14)). Despite an increasing understanding of this lymphoma subtype the clinical outcome is still poor. Objectives: The presenting features of MCL and response to chemotherapy were investigated by the authors. Results: Altogether 69 patients were diagnosed with MCL in Szeged and in Szombathely, it is about 10% of all NHL's. The mean age was 63.22±11.10 years and only five patients had 2 or worse performance score at diagnosis. Slight male predominance was observed ( 11:9). Elastic variants were described in 26 patients (37.7%). Extranodal presentation was frequent (27 pts, 39.1%). Most patients were diagnosed at advanced Ann Arbor stages III and IV (39 pts, 56.6%). Thirtysix pts recieved doxorubicin-based first-line chemotherapy. Fortyfive pts responded (26 complete and 19 partial remissions). The mean overall survival was 41.71+5.94 months and time to treatment failure was 21.97±2.9 months for the whole group. We observed only 7 second partial remissions. The time to treatment failure was longer for pts treated with doxorubicin-based chemotherapy (mean TTF: 27.1313.63 vs. 10.93+3.18 months), but only a slight benefit regarding overall survival were found (mean OS: 43.05±6.44 vs. 32.44±7.56 months) compared to the effect of other treatment protocols. Conclusions: MCL has the same features in Hungary, as in other parts of the world. The clinical outcome with conventional chemotherapy is poor, thus younger patients are candidates for high-dose chemotherapy and stem cell rescue in first remission.

AB - Background: Novel diagnostic techniques such as immunophenotyping and molecular genetic analysis have enabled us to recognize new entities such as mantle cell lymphoma (MCL). Typically, MCLs originate from CD5+/CDI9+/CD23- cells and have characteristic genetic markers (bel-1 overexpression due to t( 11 ; 14)). Despite an increasing understanding of this lymphoma subtype the clinical outcome is still poor. Objectives: The presenting features of MCL and response to chemotherapy were investigated by the authors. Results: Altogether 69 patients were diagnosed with MCL in Szeged and in Szombathely, it is about 10% of all NHL's. The mean age was 63.22±11.10 years and only five patients had 2 or worse performance score at diagnosis. Slight male predominance was observed ( 11:9). Elastic variants were described in 26 patients (37.7%). Extranodal presentation was frequent (27 pts, 39.1%). Most patients were diagnosed at advanced Ann Arbor stages III and IV (39 pts, 56.6%). Thirtysix pts recieved doxorubicin-based first-line chemotherapy. Fortyfive pts responded (26 complete and 19 partial remissions). The mean overall survival was 41.71+5.94 months and time to treatment failure was 21.97±2.9 months for the whole group. We observed only 7 second partial remissions. The time to treatment failure was longer for pts treated with doxorubicin-based chemotherapy (mean TTF: 27.1313.63 vs. 10.93+3.18 months), but only a slight benefit regarding overall survival were found (mean OS: 43.05±6.44 vs. 32.44±7.56 months) compared to the effect of other treatment protocols. Conclusions: MCL has the same features in Hungary, as in other parts of the world. The clinical outcome with conventional chemotherapy is poor, thus younger patients are candidates for high-dose chemotherapy and stem cell rescue in first remission.

UR - http://www.scopus.com/inward/record.url?scp=33748555146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748555146&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748555146

VL - 96

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11 PART II

ER -